235 related articles for article (PubMed ID: 36875551)
21. Mesothelin-targeted CAR-NK Cells Derived From Induced Pluripotent Stem Cells Have a High Efficacy in Killing Triple-negative Breast Cancer Cells as Shown in Several Preclinical Models.
Yang M; Guan T; Chen CF; He LF; Wu HM; Zhang RD; Li Y; Lin YC; Zeng H; Wu JD
J Immunother; 2023 Oct; 46(8):285-294. PubMed ID: 37584622
[TBL] [Abstract][Full Text] [Related]
22. The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice.
Zhang Q; Liu G; Liu J; Yang M; Fu J; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Zhang L; Tian X
Mol Ther Oncolytics; 2021 Mar; 20():556-568. PubMed ID: 33738341
[TBL] [Abstract][Full Text] [Related]
23. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.
Chen J; Hu J; Gu L; Ji F; Zhang F; Zhang M; Li J; Chen Z; Jiang L; Zhang Y; Shi R; Ma L; Jia S; Zhang Y; Zhang Q; Liang J; Yao S; Hu Z; Guo Z
Cancer Immunol Immunother; 2023 Feb; 72(2):409-425. PubMed ID: 35925286
[TBL] [Abstract][Full Text] [Related]
24. Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.
Cao B; Liu M; Wang L; Liang B; Feng Y; Chen X; Shi Y; Zhang J; Ye X; Tian Y; Zhi C; Li J; Lian H; Wu Q; Zhang Z
Biochem Biophys Res Commun; 2020 Mar; 524(1):96-102. PubMed ID: 31980173
[TBL] [Abstract][Full Text] [Related]
25. Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality.
Schoutrop E; Renken S; Micallef Nilsson I; Hahn P; Poiret T; Kiessling R; Wickström SL; Mattsson J; Magalhaes I
Oncoimmunology; 2022; 11(1):2093426. PubMed ID: 35898704
[TBL] [Abstract][Full Text] [Related]
26. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P
J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106
[TBL] [Abstract][Full Text] [Related]
27. Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.
Zhang E; Yang P; Gu J; Wu H; Chi X; Liu C; Wang Y; Xue J; Qi W; Sun Q; Zhang S; Hu J; Xu H
J Hematol Oncol; 2018 Aug; 11(1):102. PubMed ID: 30103775
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
[TBL] [Abstract][Full Text] [Related]
29. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
Zhu Y; Wang K; Yue L; Zuo D; Sheng J; Lan S; Zhao Z; Dong S; Hu S; Chen X; Feng M
Pharmacol Res; 2024 May; 203():107186. PubMed ID: 38641176
[TBL] [Abstract][Full Text] [Related]
30. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
Goto S; Sakoda Y; Adachi K; Sekido Y; Yano S; Eto M; Tamada K
Cancer Immunol Immunother; 2021 Sep; 70(9):2503-2515. PubMed ID: 33559069
[TBL] [Abstract][Full Text] [Related]
31. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.
Adusumilli PS; Cherkassky L; Villena-Vargas J; Colovos C; Servais E; Plotkin J; Jones DR; Sadelain M
Sci Transl Med; 2014 Nov; 6(261):261ra151. PubMed ID: 25378643
[TBL] [Abstract][Full Text] [Related]
32. Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors.
Tomar S; Zhang J; Khanal M; Hong J; Venugopalan A; Jiang Q; Sengupta M; Miettinen M; Li N; Pastan I; Ho M; Hassan R
Mol Cancer Ther; 2022 Jul; 21(7):1195-1206. PubMed ID: 35499461
[TBL] [Abstract][Full Text] [Related]
33. Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response.
Baeuerle PA; Ding J; Patel E; Thorausch N; Horton H; Gierut J; Scarfo I; Choudhary R; Kiner O; Krishnamurthy J; Le B; Morath A; Baldeviano GC; Quinn J; Tavares P; Wei Q; Weiler S; Maus MV; Getts D; Schamel WW; Hofmeister R
Nat Commun; 2019 May; 10(1):2087. PubMed ID: 31064990
[TBL] [Abstract][Full Text] [Related]
34. Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice.
Zhou X; Yang M; Yu J; Tan J; Xu N; Zhou Y; Zhang W; Ma J; Zhang Z; Friedlaender A; Taylor J; Yu L; Yan Z
J Gastrointest Oncol; 2024 Feb; 15(1):312-329. PubMed ID: 38482238
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors.
Molloy ME; Austin RJ; Lemon BD; Aaron WH; Ganti V; Jones A; Jones SD; Strobel KL; Patnaik P; Sexton K; Tatalick L; Yu TZ; Baeuerle PA; Law CL; Wesche H
Clin Cancer Res; 2021 Mar; 27(5):1452-1462. PubMed ID: 33262134
[TBL] [Abstract][Full Text] [Related]
36. Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer.
Liang Z; Dong J; Yang N; Li SD; Yang ZY; Huang R; Li FJ; Wang WT; Ren JK; Lei J; Xu C; Wang D; Wang YZ; Liang ZQ
Int J Biol Sci; 2021; 17(15):4365-4376. PubMed ID: 34803504
[TBL] [Abstract][Full Text] [Related]
37. Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor.
Zhang Z; Jiang D; Yang H; He Z; Liu X; Qin W; Li L; Wang C; Li Y; Li H; Xu H; Jin H; Qian Q
Cell Death Dis; 2019 Jun; 10(7):476. PubMed ID: 31209210
[TBL] [Abstract][Full Text] [Related]
38. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
[TBL] [Abstract][Full Text] [Related]
39. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
Lanitis E; Poussin M; Hagemann IS; Coukos G; Sandaltzopoulos R; Scholler N; Powell DJ
Mol Ther; 2012 Mar; 20(3):633-43. PubMed ID: 22127019
[TBL] [Abstract][Full Text] [Related]
40. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]